Johnson & Johnson Announces a New Name for Tremfya 100 mg in the European GI Biologics Market in Q2 2026

UCB introduced the MyTherapy Bimzelx module.

Takeda positioned Entyvio as a unique gut-focused treatment for CD and UC and introduced a new DTC campaign.

Lilly highlighted long-term Omvoh efficacy across several clinical studies.

AbbVie promoted Rinvoq’s eight immunology indications with its familiar campaign themes.

Johnson & Johnson announced the renaming of the Tremfya prefilled pen, along with a variation of a previous campaign.

Pfizer advertised Xeljanz’s cardiovascular safety evidence.